Abstract
Dynogen Pharmaceuticals Inc, under license from Mitsubishi Pharma Corp, is developing pumosetrag (MKC-733, DDP-733), an orally available gastroprokinetic agent and locally acting 5-HT3 partial agonist, for the potential treatment of irritable bowel syndrome (IBS) with constipation and nocturnal gastroesophageal reflux disease (GERD). In September 2005, Dynogen commenced a phase II proof-of-concept trial of pumosetrag in IBS with constipation; positive results were reported in February 2007 and a phase IIb trial was to start in the fourth quarter of 2007. In September 2006, the company had initiated a phase Ib trial in nocturnal GERD.
MeSH terms
-
Animals
-
Dopamine Agents / adverse effects
-
Dopamine Agents / pharmacokinetics
-
Dopamine Agents / pharmacology
-
Dopamine Agents / therapeutic use*
-
Gastroesophageal Reflux / drug therapy*
-
Gastroesophageal Reflux / metabolism
-
Gastrointestinal Agents / adverse effects
-
Gastrointestinal Agents / pharmacokinetics
-
Gastrointestinal Agents / pharmacology
-
Gastrointestinal Agents / therapeutic use*
-
Humans
-
Irritable Bowel Syndrome / drug therapy*
-
Irritable Bowel Syndrome / metabolism
-
Pyridines / adverse effects
-
Pyridines / pharmacokinetics
-
Pyridines / pharmacology
-
Pyridines / therapeutic use*
-
Quinuclidines / adverse effects
-
Quinuclidines / pharmacokinetics
-
Quinuclidines / pharmacology
-
Quinuclidines / therapeutic use*
-
Receptors, Serotonin, 5-HT3 / drug effects*
-
Receptors, Serotonin, 5-HT3 / metabolism
-
Treatment Outcome
Substances
-
Dopamine Agents
-
Gastrointestinal Agents
-
Pyridines
-
Quinuclidines
-
Receptors, Serotonin, 5-HT3
-
Pumosetrag